A morphometric analysis of hepatitis B subviral particles shows no correlation of filament proportion and length with clinical stage and genotype

J Viral Hepat. 2022 Sep;29(9):719-726. doi: 10.1111/jvh.13712. Epub 2022 Jun 7.

Abstract

It was recently suggested that the composition of circulating hepatitis B subviral particles (SVPs) could be used to differentiate the various stages in chronic hepatitis B virus (HBV) infection, with significantly lower proportions of L and M proteins in inactive carriers than in individuals with chronic hepatitis. L protein is abundant in virions and filamentous SVPs but almost absent from spherical SVPs. We, therefore, performed a morphometric analysis of SVPs in these two groups of patients, by conducting a retrospective analysis on sera from 15 inactive carriers and 11 patients with chronic hepatitis infected with various HBV genotypes. Subviral particles were concentrated by centrifugation on a sucrose cushion, with monitoring by transmission electron microscopy. The percentage of filamentous SVPs and filament length for 100 SVPs was determined with a digital camera. The L protein PreS1 promoter was sequenced from viral genomes by the Sanger method. No marked differences were found between patients, some of whom had only spherical SVPs, whereas others had variable percentages of filamentous SVPs (up to 28%), of highly variable length. High filament percentages were not associated with a particular sequence of the L protein promoter, HBV genotype or even disease stage. High levels of circulating filamentous SVPs are probably more strongly related to individual host factors than to viral strain characteristics or disease stage.

Keywords: electron microscopy; genotype; hepatitis B virus; liver disease stage; morphometric analysis; subviral particle.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Genotype
  • Hepatitis B Surface Antigens
  • Hepatitis B virus / genetics
  • Hepatitis B*
  • Hepatitis B, Chronic*
  • Humans
  • Retrospective Studies

Substances

  • Hepatitis B Surface Antigens